AKN-028   Click here for help

GtoPdb Ligand ID: 7969

Synonyms: AKN 028 | AKN028
Compound class: Synthetic organic
Comment: AKN-028 is an orally bioavailable protein tyrosine kinase inhibitor for FMS-related tyrosine kinase 3 (FLT3) and stem cell factor receptor (SCFR; KIT), that was developed for potential antineoplastic activity [1-2]. The compound inhibits wild-type and mutant FLT3 and KIT kinases.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 3
Rotatable bonds 3
Topological polar surface area 92.51
Molecular weight 302.13
XLogP 2.3
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES Nc1ncc(nc1Nc1ccc2c(c1)cc[nH]2)c1ccncc1
Isomeric SMILES Nc1ncc(nc1Nc1ccc2c(c1)cc[nH]2)c1ccncc1
InChI InChI=1S/C17H14N6/c18-16-17(22-13-1-2-14-12(9-13)5-8-20-14)23-15(10-21-16)11-3-6-19-7-4-11/h1-10,20H,(H2,18,21)(H,22,23)
No information available.
Summary of Clinical Use Click here for help
A Phase 1/II trial was registered with ClinicalTrials.gov (NCT01573247), but its status has not been updated since 2012. This was a safety study of AKN-028 in AML patients. Safety concerns (severe liver toxicity) were identified during this trial and development was terminated in 2016.